FANCELLI, SARA
 Distribuzione geografica
Continente #
EU - Europa 315
NA - Nord America 313
AS - Asia 146
AF - Africa 1
Totale 775
Nazione #
US - Stati Uniti d'America 312
IE - Irlanda 93
IT - Italia 87
HK - Hong Kong 58
PL - Polonia 54
SE - Svezia 39
CN - Cina 30
JO - Giordania 29
SG - Singapore 17
RU - Federazione Russa 12
AT - Austria 9
IN - India 9
CH - Svizzera 5
NO - Norvegia 5
GB - Regno Unito 4
DE - Germania 3
FR - Francia 2
VN - Vietnam 2
CA - Canada 1
EG - Egitto 1
FI - Finlandia 1
TR - Turchia 1
UA - Ucraina 1
Totale 775
Città #
Dublin 93
Warsaw 52
Hong Kong 44
Chandler 40
Ashburn 36
Fairfield 30
Woodbridge 17
Florence 15
Seattle 15
Cambridge 14
Altamura 13
Shanghai 13
Lawrence 12
Moscow 12
Singapore 11
Boardman 10
Houston 10
Milan 10
Wilmington 10
Vienna 9
New York 8
Beijing 7
Pune 7
Princeton 6
Boston 5
Oslo 5
Bern 4
Kent 4
Andover 3
Ann Arbor 3
Hillsboro 3
London 3
Norwalk 3
Recanati 3
San Diego 3
Anguillara Sabazia 2
Bremen 2
Chennai 2
Dong Ket 2
Falls Church 2
Livorno 2
Paris 2
Rome 2
Rufina 2
Venice 2
Acerra 1
Ancona 1
Bagno A Ripoli 1
Bari 1
Buffalo 1
Chicago 1
Krefeld 1
Lappeenranta 1
Marcallo con Casone 1
Medford 1
Padova 1
Phoenix 1
Verona 1
Wandsworth 1
Washington 1
Zurich 1
Totale 569
Nome #
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 153
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 64
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment 56
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy 56
Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor) 55
Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives 54
REBECA trial: A new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer 45
Results of the observational prospective RealFLOT study 34
Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma 32
Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer 31
Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification 28
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment 26
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population 26
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions 24
Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study 23
Liquid Biopsy and Non-small-cell Lung Cancer: Expecting More Fluid Management of Patients 21
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 18
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer 17
Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer 15
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 14
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 13
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 3
null 3
Totale 811
Categoria #
all - tutte 5.045
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.045


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202065 4 3 4 3 9 6 6 6 6 5 9 4
2020/202196 5 9 0 30 4 3 3 9 8 8 5 12
2021/202237 0 2 3 0 0 4 4 4 1 3 3 13
2022/2023308 10 36 7 27 14 53 50 39 44 7 11 10
2023/2024264 11 14 22 11 24 40 17 60 2 14 24 25
2024/202525 25 0 0 0 0 0 0 0 0 0 0 0
Totale 811